Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline

Simply Wall St.04-23

AdvertisementRecent performance snapshot Biohaven (BHVN) has recently caught investor attention after a one-month return of 22.2%, contrasting with a past three-month total return decline of 22.4% and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629000606?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-23 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629000606","market":"hk","top_or_hot":-1,"title":"Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent performance snapshot Biohaven (BHVN) has recently caught investor attention after a one-month return of 22.2%, contrasting with a past three-month total return decline of 22.4% and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-sharp-one-month-rebo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-23 14:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-sharp-one-month-rebo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent performance snapshot Biohaven (BHVN) has recently caught investor attention after a one-month return of 22.2%, contrasting with a past three-month total return decline of 22.4% and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-sharp-one-month-rebo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-sharp-one-month-rebo","article_id":"2629000606","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/assessing-biohaven-bhvn-valuation-after-sharp-one-month-rebo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629000606","pubTimestamp":1776924494,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent performance snapshot\nBiohaven (BHVN) has recently caught investor attention after a one-month return of 22.2%, contrasting with a past three-month total return decline of 22.4% and a one-year total return decline of 50.1%.\nSee our latest analysis for Biohaven.\nThe recent 22.2% one month share price return, alongside a 4.8% one day gain at a share price of US$10.68, contrasts with a 50.1% one year total shareholder return decline. This suggests short term momentum after a tougher period...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4139":"生物科技"},"translate_title":"在一个月大幅反弹和一年大幅下跌后评估Biohaven(BHVN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1.5},"content_text":"AdvertisementRecent performance snapshot Biohaven (BHVN) has recently caught investor attention after a one-month return of 22.2%, contrasting with a past three-month total return decline of 22.4% and a one-year total return decline of 50.1%. See our latest analysis for Biohaven. The recent 22.2% one month share price return, alongside a 4.8% one day gain at a share price of US$10.68, contrasts with a 50.1% one year total shareholder return decline. This suggests short term momentum after a tougher period for longer term holders. If you are looking beyond Biohaven for more ideas in healthcare and biotech, this is a good moment to scan 35 healthcare AI stocks With Biohaven still loss making, a market cap of about US$1.5b and a recent share price of US$10.68, the key question is whether this pullback leaves potential upside on the table or if the market is already pricing in future growth. Preferred Price to Book Multiple of 30.9x: Is it justified? Biohaven currently trades on a P/B of 30.9x, which is substantially higher than both the broader US biotechs industry and its closer peer group. The P/B ratio compares a company’s market value with its book value, so a higher figure often reflects strong expectations about future assets, earnings power or both. For a loss making biopharma business with minimal revenue and a large development pipeline, it usually means investors are placing significant weight on potential future treatments rather than current financials. For Biohaven, the current 30.9x P/B sits far above the US biotechs industry average of 2.5x and the peer average of 3.9x. This suggests that the market is assigning a very rich premium compared with sector norms. With no meaningful revenue reported and the company expected to remain unprofitable over the next three years, that premium appears to be supported mainly by confidence in the pipeline and future clinical or commercial milestones rather than near term earnings. See what the numbers say about this price — find out in our valuation breakdown. Result: Price to book ratio of 30.9x (OVERVALUED) However, this premium rests on a zero revenue base and a US$738.822m net loss, so any clinical, regulatory or funding setback could quickly challenge the current story. Find out about the key risks to this Biohaven narrative. Next Steps Given the mixed tone of recent performance and valuation, it makes sense to check the underlying data yourself and decide how comfortable you are with the risk profile. Before making any move, review the 4 important warning signs. Looking for more investment ideas? If Biohaven has you thinking differently about risk and reward, do not stop here. Use this momentum to size up other opportunities that match your style.  Spot potential value opportunities early by scanning companies on attractive terms using the 61 high quality undervalued stocks. Prioritise resilience and sleep easier at night by checking out the 73 resilient stocks with low risk scores. Hunt for underfollowed stories with solid fundamentals through the screener containing 23 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biohaven might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629000606","isCrawlerRequest":true}